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Summary
Background No somatic treatment has been found to be 
effective for chronic fatigue syndrome (CFS). 
Antidepressant therapy is commonly used. Fluoxetine is 
recommended in preference to tricyclic agents because it 
has fewer sedative and autonomic nervous system effects. 
However, there have been no randomised, placebo- 
controlled, double-blind studies showing the effectiveness 
of antidepressant therapy in CFS. We have carried out such 
a study to assess the effect of fluoxetine in depressed and 
non-depressed CFS patients.
Methods In this randomised, double-blind study, we 
recruited 44 patients to the depressed CFS group, and 
52 to the non-depressed CFS group. In each group 
participants were randomly assigned to receive either 
fluoxetine (20 mg once daily) or placebo for 8 weeks. The 
effect of fluoxetine was assessed by questionnaires, self­
observation lists, standard neuropsychological tests, and a 
motion-sensing device (Actometer), which were applied on 
the day treatment started and on the last day.
Findings The two groups were well matched in terms of 
age, sex distribution, employment and marital status, and 
duration of CFS. There were no significant differences 
between the placebo and fluoxetine-treated groups in the 
change during the 8-week treatment period for any 
dimension of CFS. There was no change in subjective 
assessments of fatigue, severity of depression, functional 
impairment, sleep disturbances, neuropsychological 
function, cognitions, or physical activity in the depressed 
or the non-depressed subgroup.
Interpretation Fluoxetine in a 20 mg daily dose does not 
have a beneficial effect on any characteristic of CFS. The 
lack of effect of fluoxetine on depressive symptoms in CFS 
suggests that processes underlying the presentation of 
depressive symptoms in CFS may differ from those in 
patients with major depressive disorder.
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Introduction
Chronic fatigue syndrome (CFS) is characterised by 
persisting, disabling fatigue that does not subside with 
rest in bed and for which no medical explanation can be 
offered. As yet, no effective somatic treatment for CFS is 
known. Various drugs have been proposed for treatment 
of C F S 1“1 and antidepressants (notably fluoxetine) are 
commonly prescribed. CFS patients may tolerate first- 
generation tricyclic antidepressants poorly because side- 
effects include sedation and exacerbation of fatigue 
symptoms.5 Lynch and colleagues6 suggested the use of 
fluoxetine since this drug has fewer sedative and 
autonomic nervous system side-effects. Case-reports and 
uncontrolled studies suggested that fluoxetine is beneficial 
in C FS.2 Lynch et al0 reported that after 8 weeks of 
treatment a third of the mildly to moderately depressed 
CFS patients treated with fluoxetine showed reduction of 
at least 50% in severity of depressive symptoms, and 
another third showed between 25% and 50% reduction in 
symptom severity. However, the effectiveness of fluoxetine 
(or any other antidepressant) in the treatment of CFS has 
not been established in controlled studies.
In a previous study,7 we developed and tested a 
multidimensional assessment method for CFS, which 
assessed the behavioural, cognitive, emotional, and social 
features of CFS. These dimensions proved to be 
independent of each other and contributed to die 
description of the patient. Therefore, in an intervention 
study both the effect of treatment on fatigue severity and 
other dimensions are of interest. We have assessed the 
effect of fluoxetine on the dimensions of CFS in a 
randomised, placebo-controlled, double-blind study. 
Fluoxetine is effective in treating depressive symptoms; 
since a proportion of patients with CFS have depression, 
two groups of patients were included—a depressed CFS 
group and a non-depressed CFS group. This design 
allowed us to separate any indirect effect of fluoxetine on 
fatigue and other dimensions through improvement in 
depression from a direct effect of fluoxetine.
Patients and methods
Patients
Patients had to fulfil criteria for C F S 8 and give informed written 
consent. Patients were random ly selected from our C FS 
database, acquired through self-referral, or referral by family 
doctors, to the outpatient clinic of the D ep artm en t of General 
Internal M edicine, University Hospital Nijmegen. Patients had 
to have had fatigue for more than 1 year with substantial 
im pairm ent in their daily life, which means a score of 35 or more 
on the subjective fatigue subscale of the checklist individual 
strength.7 Depressed patients had to have a diagnosis of  major 
depressive disorder1' and a score on the Beck depression inventory 
of 16 or more (moderately to severely depressed). N on-depressed  
patients had to have a score on the Beck depression inventory of 
10 or less (no depressive feelings at all). Psychiatric examination 
(SGSV supervised by FG Z ) used a s tructured  psychiatric 
interview. Fatigue and loss of energy were not counted  as 
symptoms either in making the diagnosis of major depressive 
disorder or in calculating Beck depression inventory score.
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Exclusion criteria were: any physical illness that could explain 
the complaints; any psychiatric diagnosis besides major 
depressive disorder in depressed patients; any psychiatric 
diagnosis in non-depressed patients; pregnancy or lactation; lack 
of contraception in wom en of childbearing age; previous 
exposure to fluoxetine in a formal clinical trial; previous lack of 
satisfactory response to an adequate course of fluoxetine 
treatm ent; participation in recent clinical trials; use of any 
prescribed medication except incidental analgesics that could not 
be stopped; and current psychotherapy.
Design
In each group patients were randomly assigned, in a double-blind 
m anner, either fluoxetine or placebo by kit num ber  (provided by 
Lilly Research Centre  C T  Supply G roup, W indlesham, U K ) per 
block of ten. Fluoxetine capsules (20 mg) were taken once a day. 
D uration  of trea tm ent with fluoxetine or placebo was 8 weeks. 
Com pliance and side-effects were assessed after 1 week, 2 weeks, 
and 6 weeks of treatm ent (figure 1). Blood samples were taken 
after 2 weeks of treatm ent for m easurem ent of fluoxetine 
concentrations by a high-performance liquid chromatography 
system with spectrophotom etric  detection at 230 nm. To assess 
changes in C FS  features, the tests were done on the day 
trea tm ent started (pretreatment) and on the last day of treatm ent 
(post-treatment). Follow-up testing took place 2 m onths after 
treatm ent had stopped to assess the stability of possible effects of 
fluoxetine. T h e  study was approved by the ethics comm ittee of 
the hospital.
Psychological tests
T h e  subjective feeling of fatigue was m easured by the subjective 
fatigue subscale of the checklist individual s trength .7 O n the self­
observation list, fatigue was m easured 4 times a day on a 4-point 
scale (daily observed fatigue score). Patients completed the self- 
observation list during  the 12 days before the start of treatment, 
during  the last 12 days of treatm ent, and during the 12 days 
before follow-up testing. T h e  scores were com bined as one 
prim ary outcom e measure.
T h e  Beck depression inventory10,11 was used to measure severity 
of depression. T h e  sym ptom  checklist is an indicator of 
psychological well-being.12 T h e  total score was used as the 
prim ary outcom e measure.
T h e  sickness im pact profile13-“ measures the influence of 
symptoms in different areas of daily functioning. T h e  total score 
was used as the prim ary outcom e measure.
T h e  physical activities subscale of the checklist individual 
strength measures the extent of  physical activity. O n the 12-day 
self-observation list, physical activity is rated daily on a 7-point 
scale (daily observed activity score). Patients wore a m otion- 
sensing device (the Actometer), day and night, during  this
Placebo (n=53) Fluoxetine (n=54)
Trial completed 41(96%) 45 (83%)
Skin reactions 1(2%) 3(6%)
Haematoma # • 1(2%)
Nausea •  • 2(4%)
Headache 1(2%) 2(4%)
Personal reason •  • 1(2%)
Table 1: Patients entering trial and reasons for dropout
12-day period. T h e  Actometer is the size of a matchbox and 
attached to the ankle; it measures the num ber  of movements in 
5-minute periods. Data are read by a personal com puter  and 
m ean is calculated as the primary outcom e measure.
T h e  subscale on sleep problems of the symptom checklist12 was 
used. O n the 12-day self-observation list, quality of sleep (slept 
well, difficulty falling asleep, restless sleep, early awakening in the 
morning) is recorded daily (daily observed quality of  sleep 
scores). Each score is expressed as a percentage of occurrence. A 
special sleep pattern  observation list was completed in 
combination with the 12-day self-observation list and Actometer 
readings. Patients recorded daily, every 30 min, whether they 
were resting, asleep, or awake. T h e  following variables were 
calculated over the 12-day period: hours asleep at night, hours 
asleep during the day, hours awake before falling asleep, 
hours awake during the night, hours staying in bed after waking 
up in the m orning, and hours resting during the day (daily 
observed sleep pattern  scores). T h e  daily observed sleep quality 
score was used as the primary outcom e measure.
Neuropsychological functioning was measured by the 
concentration subscales of the checklist individual strength and 
the sickness impact profile. M em ory  and concentration 
complaints were rated daily on the 12-day self-observation list. 
This  feature was also assessed by standard neuropsychological
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Figure 2: Subjective fatigue scores and Beck depression 
inventory scores in four study groups
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Placebo Fluoxetine Placebo Fluoxetine
depressed depressed non-depressed non-depressed
(n=23) (n=21) (n=28) (n=24)
Age (years) 38-5 (10-1) 39-9 (8-6) 37-8 (11-9) 39-8(7-4)
Sex (M /F ) 5/18 3/18 9/19 6/18
Median (range) duration
of complaints years 6 (2-20) 5 ( 1-30) 6(2-30) 5(1-20)
Marital status
Married/cohabiting 19 ( 38%) 14(67%) 16(57%) 19(79%)
Divorced 1(4%) 2(9%) 1 (4%) 2(8%)
Widowed 0 1 (5%) 1(4%) 0
Single 3(13%) 4 ( 19%) 10(35%) 3(13%)
Employment status
Working 2(9%) 2 ( 10%) 9 ( 32%) 4(17%)
Housewife 7 ( 30%) 3 ( 14%) 3(11%) 4(17%)
Unemployed 2 (9%) 1(5%) 0 0
Disablement benefits/ 11 (48%) 15(71%) 13(46%) 16(66%)
sick leave
Other 1 (4%) 0 3(11%) 0
Table 2: Demographic data
tests. Speed of information processing was measured by the 
complex reaction-time test which consisted of three consecutive 
tasks of increasing complexity; reaction time and m otor speed 
were separately registered. Baseline reaction time was the 
prim ary outcom e measure for this dimension.
General questions were asked about satisfaction in social life 
and difficulties in social relationships. T h e  social interactions 
subscale of the sickness impact profile was used as the primary 
outcom e measure.
Sense of control over symptoms (self-efficacy expectations) 
were m easured by a specific question (5-point scale) and the 
internal attributions subscale of the multidimensional health 
locus of control questionnaire .15 ,b T h e  modified pain cognition 
list17 measured fatigue-related cognitions; it contained five 
subscales: suffering, catastrophising, confidence in medical care, 
resignment, and positive expectations. T h e  prim ary outcom e 
measure was self-efficacy expectations.
K now n side-effects of  fluoxetine (nausea, headache, 
nervousness, sleep disturbances, gastrointestinal disorders, dry 
m outh , anxiety, dizziness, tremor, perspiration, and weight loss) 
resemble symptoms com m only seen in C FS. Therefore, these 
complaints were assessed with a special side-effects probing list 
before trea tm ent had started, after 2 weeks, after 6 weeks, and at 
the end of treatment. Each item was rated as: never, a few times a 
m onth , a few times a week, or every day. Inform ation on 
sociodemographic data and duration of complaints was collected. 
At post-treatm ent and at follow-up, self-reported change 
com pared  with pre trea tm ent was assessed (completely recovered, 
improved, no change, deteriorated).
Analysis
Since the characteristics of C FS are independent, the effect of 
treatm ent can be assessed individually for each. To prevent type I 
error because of multiple testing, the num ber  of measures was 
reduced by selecting one prim ary outcom e measure per 
characteristic to be used in the analyses. Only patients who 
completed the trial were included in the analyses. Skewed
Recovered Improved Unchanged Worse
Post-treatment
PL-D (n=23) 0 3 ( 13%) 14(61%) 6(26%)
FL-D (n=21) 0 1 (5%) 12(57%) 8 ( 38%)
PL-ND (n=28) 0 3(11%) 21(75%) 4 ( 14%)
FL-ND (n=23) 0 2(8%) 13(57%) 8 ( 35%)
Follow-up
PL-D (n=23) 0 3(13%) 12(52%) 8(35%)
FL-D (n=21) 0 3 ( 14%) 13(62%) 5 ( 24%)
PL-ND (n=28) 0 2(7%) 22(79%) 4 ( 14%)
FL-ND (n=24) 0 5(21%) 17(71%) 2 ( 8%)
PL-D= placebo-depressed; FL-D=fluoxetine-depressed; PL-ND=placebo-non-depressed; 
FL-ND=fluoxetine-non-depressed. Percentages are row percentages.
Table 3: Self-reported change reported at post-treatment and 
follow-up testing
variables were log-transformed to produce approximately normal 
distributions. T h e  effect of fluoxetine was assessed by ANOVA of 
the difference in scores between pre trea tm ent and post-treatm ent 
testing of each primary outcom e measure. Two main effects were 
calculated— drug  effect (fluoxetine vs placebo) and condition 
effect (depressed vs non-depressed). T h e  interaction effect 
between drug  and condition effects was also calculated. If 
ANOVA showed a significant effect of a certain characteristic, 
explorative analysis was done on the other variables of that 
characteristic. T h e  stability of possible treatm ent effects was 
assessed by ANOVA of the difference in scores between 
pretreatm ent and follow-up testing. Sociodemographic variables 
were com pared by the x2 test or th e Kruskal-Wallis test when 
appropriate. Because there were nine comparisons the p value 
was set at 0-01 for a two-tailed test to prevent type I error. 
Analyses were completed before die code was broken.
Results
48 depressed patients (9 men, 39 women) and 59 non­
depressed patients (18 men, 41 women) entered the trial. 
Of the 107 patients, 96 completed the trial. 15% of 
patients in the fluoxetine group stopped treatment 
because of side-effects versus 4% of placebo-treated 
patients (table 1). There were no significant differences 
between the groups in employment or marital status, sex, 
age, or duration of complaints (table 2).
There was no difference between the fluoxetine-treated 
group and placebo groups in the change from 
pretreatment to post-treatment for any primary outcome 
measure assessing subjective fatigue (figure 2), depression 
(figure 2), psychological well-being, functional impair­
ment, physical activity, sleep disturbances, neuro­
psychological functioning, social interactions, or 
cognitions. The mean differences between fluoxetine and 
placebo in improvement in fatigue severity and depression 
severity were —0-164 (95% Cl -0 -6 4  to 0-31) and 
-0 -1 8 6  ( -0 -3 5  to -0 -0 2 ) ,  respectively. Thus, in the most 
extreme case fluoxetine would yield an improvement of 
0*31' (3%) in fatigue and 2% in depression severity. In 
both cases the improvement is not clinically meaningful. 
This study therefore has sufficient power.
At follow-up there were no differences between the 
fluoxetine-treated and placebo groups for any variable 
assessing the characteristics of subjective fatigue or 
depression (figure 2).
No patient reported complete recovery (table 3). There 
was a trend for a drug effect on self-reported change 
at post-treatment (p=0-052), when patients from the 
fluoxetine group were more likely to report deterioration. 
There were no effects on self-reported change at follow- 
up testing.
After 2 and 6 weeks of treatment, there were no 
differences between the actively treated and placebo 
groups in the frequency of any of the possible fluoxetine 
side-effects. At the end of treatment, more fluoxetine- 
treated than placebo-treated patients complained of 
tremor (drug effect, p=0-006) and perspiration (drug 
effect, p=0-008). For complaints that occurred at least a 
few times a week, 10 (22%) of fluoxetine-treated patients 
complained of tremor and 23 (51%) complained of 
perspiration at the start of treatment (placebo group, 12 
[24%] and 17 [33%], respectively). At post-treatment, 18 
(40%) of fluoxetine-treated patients complained of tremor 
and 67% of perspiration (placebo group, 30 [26%] and 
20 [40%], respectively).
Fluoxetine was detected in plasma in all patients of the 
fluoxetine group (median 40 mg/L [range 13-134]), but 
in no patients of the placebo group.
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Discussion
This is the first randomised, placebo-controlled, double­
blind study of the effect of antidepressant therapy in CFS. 
We assessed the effect of fluoxetine not only on fatigue or 
depression, but also on other characteristics of CFS. 
Despite previous promising results we found that 
fluoxetine does not have a beneficial effect on any 
characteristic of CFS (fatigue severity, depression severity, 
functional impairment, sleep disturbances, neuro­
psychological functioning, cognitions, or physical activity). 
Fluoxetine was not superior to placebo for any feature of 
CFS. There have been anecdotal reports that fluoxetine is 
poorly tolerated by patients with CFS. In our trial, 15% of 
fluoxetine-treated patients withdrew because of side- 
effects, a higher withdrawal rate than in fluoxetine trials in 
depressed patients on the same regimen (5-10% ).18-20 Side- 
effect assessments showed that there was a significantly 
greater increase in the frequency of tremor and 
perspiration during the treatment period, compared with 
pretreatment, in the fluoxetine group. We found that, in 
patients with several complaints, the frequencies of side- 
effects before treatment must be taken into account. Many 
patients reported side-effects at the end of treatment, but 
most of them had reported these complaints before 
treatment started.
We do not know whether a dose higher than the 20 mg 
daily we used may yield a better effect. No dose-effect 
relation in fluoxetine has been established, and a dose of
5 mg daily is effective in major depressive disorder.21 In 
depressed patients, an increase of the dose to 60 mg daily 
in those who did not respond to 20 mg daily was no more 
effective than continuation.22-24 In our study 20 mg daily 
was ineffective for CFS, and side-effects caused 15% of 
patients to withdraw. Higher doses of fluoxetine may cause 
higher drop-out rates because of increased side-effects.21 
The lack of effect of fluoxetine on depressive symptoms is 
surprising. G ram ’s review of the effectiveness of fluoxetine 
in depressed patients21 concluded that fluoxetine is an 
effective antidepressant. However, in our study fluoxetine 
was no better than placebo in treating depression. This 
finding cannot be explained by differences in pretreatment 
depression severity or by non-compliance. At intake, 
patients were diagnosed as depressed according to DSM  
III-R criteria, which include affective, somatic, and 
cognitive symptoms.9 Somatic symptoms and cognitive 
symptoms are commonly reported by patients with CFS, 
irrespective of whether they are depressed, and therefore 
these symptoms may not be related to disturbed mood in 
CFS. Moreover, Beck depression inventory score is also 
based on these three symptom groups, and an effect of 
fluoxetine on affective symptoms might then be masked by 
the absence of an effect on cognitive and somatic 
symptoms. To test this hypothesis we did additional 
analyses on three subsets of Beck depression inventory 
items, divided into affective, cognitive, and somatic items. 
In the fluoxetine group there were no significant changes 
in any of these subscores.
Our results have theoretical implications on the role 
of depression in CFS. There may be differences in 
underlying processes of depressive symptoms between 
CFS patients with depressive comorbidity and patients 
with major depressive disorder. Even the presentation of 
affective symptoms may not imply disturbed mood in CFS 
as it does in major depressive disorder. Fluoxetine is a 
selective serotonin reuptake inhibitor. We found that in 
depressed CFS patients disturbed serotonin processes are
unlikely to be involved in the presentation of depression­
like symptoms. This conclusion is supported by a study of 
serotonin processes in CFS.25 Yatham et al found no 
differences in fenfluramine-induced prolactin and cortisol 
responses between CFS patients and healthy controls.
We conclude that prescription of 20 mg fluoxetine in 
CFS is unwarranted, irrespective of whether depressive 
symptoms are present; it does not lead to improvement in 
any area of the patient’s functioning.
This study was sponsored by Eli Lilly, Netherlands. We thank 
Miriam Verberne for her help during data collection and A H Veefkind of 
Psychiatric Centre Zon «Si Schild, Amersfoort, Netherlands, for 
measurements of fluoxetine concentrations.
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